Aspen Pharmacare Holdings Dirección
Dirección controles de criterios 4/4
El CEO de Aspen Pharmacare Holdings es Stephen Saad , nombrado en Jan 2000, tiene una permanencia de 24.83 años. compensación anual total es ZAR27.30M, compuesta por 35.2% salario y 64.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 11.82% de las acciones de la empresa, por valor de ZAR8.94B. La antigüedad media del equipo directivo y de la junta directiva es de 7.7 años y 5.6 años, respectivamente.
Información clave
Stephen Saad
Chief Executive Officer (CEO)
R27.3m
Compensación total
| Porcentaje del salario del CEO | 35.2% |
| Permanencia del CEO | 24.8yrs |
| Participación del CEO | 11.8% |
| Permanencia media de la dirección | 7.7yrs |
| Promedio de permanencia en la Junta Directiva | 5.6yrs |
Actualizaciones recientes de la dirección
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01
Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02Recent updates
Aspen Pharmacare Holdings Limited (JSE:APN) Not Lagging Market On Growth Or Pricing
Nov 09Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings
Oct 10Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden
Oct 01Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59
Sep 10We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt
May 08Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable
Mar 05Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Dec 22Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | R27m | R10m | R4b |
| Mar 31 2024 | n/a | n/a | R5b |
| Dec 31 2023 | n/a | n/a | R5b |
| Sep 30 2023 | n/a | n/a | R5b |
| Jun 30 2023 | R24m | R9m | R5b |
| Mar 31 2023 | n/a | n/a | R6b |
| Dec 31 2022 | n/a | n/a | R6b |
| Sep 30 2022 | n/a | n/a | R6b |
| Jun 30 2022 | R23m | R9m | R6b |
| Mar 31 2022 | n/a | n/a | R6b |
| Dec 31 2021 | n/a | n/a | R6b |
| Sep 30 2021 | n/a | n/a | R5b |
| Jun 30 2021 | R24m | R8m | R5b |
| Mar 31 2021 | n/a | n/a | R4b |
| Dec 31 2020 | n/a | n/a | R4b |
| Sep 30 2020 | n/a | n/a | R4b |
| Jun 30 2020 | R23m | R8m | R3b |
| Mar 31 2020 | n/a | n/a | R3b |
| Dec 31 2019 | n/a | n/a | R870m |
| Sep 30 2019 | n/a | n/a | R1b |
| Jun 30 2019 | R14m | R8m | R2b |
| Mar 31 2019 | n/a | n/a | R3b |
| Dec 31 2018 | n/a | n/a | R5b |
| Sep 30 2018 | n/a | n/a | R5b |
| Jun 30 2018 | R17m | R7m | R6b |
Compensación vs. Mercado: La compensación total ($USD1.51M) de Stephen está en línea con el promedio de empresas de tamaño similar en el mercado ZA ($USD1.51M).
Compensación vs. Ingresos: La compensación de Stephen ha sido consistente con los resultados de la empresa en el último año.
CEO
Stephen Saad (60 yo)
24.8yrs
Permanencia
R27,303,000
Compensación
Mr. Stephen Bradley Saad, BCom, CA(SA), serves as the Group Chief Executive Officer of Aspen Pharmacare Canada Inc. Mr. Stephen has been the Group Chief Executive Officer of Aspen Pharmacare Holdings Limit...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Group CEO & Executive Director | 24.8yrs | R27.30m | 11.82% ZAR 8.9b | |
| Group CFO & Executive Director | 25.8yrs | R16.66m | sin datos | |
| Group Chief Operations Officer & Responsible Pharmacist | 11yrs | R17.18m | sin datos | |
| Group Chief Advisor | 2.8yrs | R11.14m | 4.32% ZAR 3.3b | |
| Group Chief Corporate Services Officer & Executive Director | less than a year | R13.79m | sin datos | |
| Group Chief Strategic Development Officer | 4.5yrs | R12.81m | sin datos | |
| Investor Relations Manager | no data | sin datos | sin datos | |
| Group Company Secretary & Chief of Staff | less than a year | sin datos | sin datos | |
| Regional Chief Executive Officer of Asia Pacific | 10.8yrs | sin datos | sin datos | |
| Chief Executive Officer of Aspen Global Incorporated | 7.7yrs | sin datos | sin datos | |
| Corporate Affairs & Investor Relations Executive | no data | sin datos | sin datos |
7.7yrs
Permanencia media
54.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de APN es experimentado (7.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Group CEO & Executive Director | 25.8yrs | R27.30m | 11.82% ZAR 8.9b | |
| Group CFO & Executive Director | 2.8yrs | R16.66m | sin datos | |
| Group Chief Corporate Services Officer & Executive Director | less than a year | R13.79m | sin datos | |
| Lead Independent Non-Executive Director | 5.6yrs | R1.27m | sin datos | |
| Non-Executive Director | 25.8yrs | R551.00k | sin datos | |
| Independent Non-Executive Chairman | 12.6yrs | R1.49m | sin datos | |
| Independent Non-Executive Director | 2.9yrs | R1.08m | sin datos | |
| Non-Executive Director | 9.8yrs | R427.00k | sin datos | |
| Independent Non-Executive Director | 6.3yrs | R1.14m | sin datos | |
| Independent Non-Executive Director | less than a year | R183.00k | sin datos | |
| Independent Non-Executive Director | 5.6yrs | R432.00k | sin datos |
5.6yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de APN se considera experimentada (5.6 años de antigüedad promedio).